Compare HUIZ & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUIZ | VNRX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 18.9M |
| IPO Year | 2019 | 2012 |
| Metric | HUIZ | VNRX |
|---|---|---|
| Price | $1.75 | $3.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $2.30 | $1.67 |
| AVG Volume (30 Days) | 8.8K | ★ 514.4K |
| Earning Date | 06-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,727,384.00 |
| Revenue This Year | $8.58 | $355.66 |
| Revenue Next Year | $6.64 | $849.08 |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | N/A | ★ 40.04 |
| 52 Week Low | $1.19 | $0.13 |
| 52 Week High | $4.16 | $2.89 |
| Indicator | HUIZ | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.95 | 77.26 |
| Support Level | $1.54 | $0.22 |
| Resistance Level | $1.93 | N/A |
| Average True Range (ATR) | 0.20 | 0.28 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 56.43 | 94.09 |
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.